JP2012501318A - 上皮性卵巣癌の診断又は予後診断方法 - Google Patents

上皮性卵巣癌の診断又は予後診断方法 Download PDF

Info

Publication number
JP2012501318A
JP2012501318A JP2011524451A JP2011524451A JP2012501318A JP 2012501318 A JP2012501318 A JP 2012501318A JP 2011524451 A JP2011524451 A JP 2011524451A JP 2011524451 A JP2011524451 A JP 2011524451A JP 2012501318 A JP2012501318 A JP 2012501318A
Authority
JP
Japan
Prior art keywords
eoc
sox11
binding moiety
ovarian cancer
epithelial ovarian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011524451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501318A5 (enExample
Inventor
カール・アーネ・クリステル・ボレベック
サラ・シャルロット・アンデルソン・エーコー
ドナル・ジョン・ブレナン
Original Assignee
イミュノヴィア・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノヴィア・アーベー filed Critical イミュノヴィア・アーベー
Publication of JP2012501318A publication Critical patent/JP2012501318A/ja
Publication of JP2012501318A5 publication Critical patent/JP2012501318A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G01N33/57545—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011524451A 2008-09-01 2009-09-01 上皮性卵巣癌の診断又は予後診断方法 Pending JP2012501318A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0815846.1 2008-09-01
GBGB0815846.1A GB0815846D0 (en) 2008-09-01 2008-09-01 diagnosis, prognosis and imaging of disease
PCT/GB2009/002098 WO2010023458A1 (en) 2008-09-01 2009-09-01 Method of diagnosing or prognosing epithelial ovarian cancer

Publications (2)

Publication Number Publication Date
JP2012501318A true JP2012501318A (ja) 2012-01-19
JP2012501318A5 JP2012501318A5 (enExample) 2012-10-18

Family

ID=39866018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524451A Pending JP2012501318A (ja) 2008-09-01 2009-09-01 上皮性卵巣癌の診断又は予後診断方法

Country Status (7)

Country Link
US (4) US20110217238A1 (enExample)
EP (1) EP2329042B1 (enExample)
JP (1) JP2012501318A (enExample)
CN (1) CN102186994A (enExample)
ES (1) ES2605254T3 (enExample)
GB (1) GB0815846D0 (enExample)
WO (1) WO2010023458A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101680896A (zh) 2007-03-27 2010-03-24 伊缪诺维亚公司 检测腺癌的蛋白标志/标记
GB0910620D0 (en) * 2009-06-19 2009-08-05 Immunovia Ab Agents and uses thereof
US9230153B2 (en) 2011-07-20 2016-01-05 Mikroscan Technologies, Inc. Networkbased pathology system with desktop slide scanner
WO2013176958A1 (en) * 2012-05-21 2013-11-28 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
EP3069183A4 (en) 2013-11-15 2017-06-28 Mikroscan Technologies Inc. Geological scanner
WO2016069794A1 (en) 2014-10-28 2016-05-06 Mikroscan Technologies, Inc. Microdissection viewing system
US20170097355A1 (en) * 2015-10-06 2017-04-06 University Of Washington Biomarkers and methods to distinguish ovarian cancer from benign tumors
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1644522A2 (en) * 2003-07-02 2006-04-12 Novartis AG Genes regulated in ovarian cancer as prognostic and therapeutic targets
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002417A2 (en) * 2003-06-20 2005-01-13 Avalon Pharmaceuticals, Inc. Cancer -linked gene aas target for chemotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5011012559; ＥＫ　Ｓ: 'ＮＵＣＬＥＡＲ　ＥＸＰＲＥＳＳＩＯＮ　ＯＦ　ＴＨＥ　ＮＯＮ-Ｂ-ＣＥＬＬ　ＬＩＮＥＡＧＥ　ＳＯＸ１１　ＴＲＡＮＳＣＲＩＰＴＩＯＮ　ＦＡＣＴＯＲ　以下備考' ＢＬＯＯＤ Ｖ１１１　Ｎ２, 20071012, Ｐ８００-８０５, ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＯＦ　ＨＥＭＡＴＯＬＯＧＹ *

Also Published As

Publication number Publication date
US20220390452A1 (en) 2022-12-08
EP2329042A1 (en) 2011-06-08
EP2329042B1 (en) 2016-10-26
GB0815846D0 (en) 2008-10-08
US20110217238A1 (en) 2011-09-08
US20160047815A1 (en) 2016-02-18
WO2010023458A1 (en) 2010-03-04
CN102186994A (zh) 2011-09-14
US20190018016A1 (en) 2019-01-17
ES2605254T3 (es) 2017-03-13

Similar Documents

Publication Publication Date Title
US20220390452A1 (en) Method of diagnosing or prognosing epithelial ovarian cancer
US20100093558A1 (en) Cancer biomarkers
CN102549169A (zh) 子宫内膜癌的标记物
Wang et al. Expression of hepatic Wnt5a and its clinicopathological features in patients with hepatocellular carcinoma
EP2742358A1 (en) Methods for diagnosing cancer
JP2019510974A (ja) 癌検出のためのヌクレオソーム−転写因子複合体の使用
US9388469B2 (en) Sox11 expression in malignant lymphomas
CN105158468B (zh) Ck19联合ov6在制备肝癌分子分型试剂盒及肝癌个体化治疗中的应用
US12298307B2 (en) PD-ECGF as biomarker of cancer
Amer et al. DDX43 mRNA expression and protein levels in relation to clinicopathological profile of breast cancer
US20060134622A1 (en) Amplified cancer target genes useful in diagnosis and thereapeutic screening
US20230133776A1 (en) Methods for diagnosing cancer
Wang et al. ERBB‐2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas
EP2269073B1 (en) A method of assessing cancer status in a breast cancer patient
JPWO2010117010A1 (ja) 腫瘍マーカーおよびその利用
Balar et al. MULTIMODALITY TESTING OF HER2/NEU MARKER IN BREAST CANCER: A CORRELATIVE STUDY
US9784743B2 (en) Collagens as markers for breast cancer treatment
CN119269806A (zh) Ciapin1在胶质瘤的诊断或预后中的应用及相关的计算机可读介质
CA3227281A1 (en) Methods and compositions related to mcl-1 and bim heterodimer antibodies
US8241862B2 (en) Perinucleolar compartment as a cancer marker
Domínguez-Escrig et al. Clinical Scenario: Initial High-Grade Ta Tumor: 45-Year-old healthy man with his first large, high-grade Ta cancer
JPWO2019021654A1 (ja) 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140521

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151005